These encouraging results as a monotherapy promoted the development of a phase Ib/II clinical trial to determine the safety, tolerability, and antileukemic activity in combination with azacitidine and/or venetoclax in patients with relapsed and CD123+ AML (NCT04086264). This evidence concerns the gene IL3RA and acute myeloid leukemia.